Perhexiline maleate and peripheral neuropathy.

Abstract

Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris. In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder. Improvement was noted with cessation of therapy. In a few cases the presence of active denervation signified a poor prognosis, with only slight improvement. The underlying mechanism causing the neuropathy is not yet fully known, although some evidence indicates that it may be a lipid storage process.

• Authors: P Bouche, M G Bousser, M A Peytour, H P Cathala
• Journal: Neurology (Neurology) Vol. 29 Issue 5 Pg. 739-43 (May 1979) ISSN: 0028-3878 [Print] United States
• PMID: 220563 (Publication Type: Journal Article)

Chemical References

• Piperidines
• Perhexiline

Topics

• Adult
• Aged
• Angina Pectoris (prevention & control)
• Electromyography
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Motor Neurons (drug effects)
• Muscular Atrophy (chemically induced)
• Neural Conduction (drug effects)
• Perhexiline (adverse effects, therapeutic use)
• Peripheral Nervous System Diseases (chemically induced, physiopathology)
• Peroneal Nerve (physiopathology)
• Piperidines (adverse effects)
• Ulnar Nerve (physiopathology)